NCT02177786

Brief Summary

The primary objective of this study is to determine the effect of selonsertib (formerly GS-4997) on estimated glomerular filtration rate (eGFR) decline in participants with diabetic kidney disease (DKD). Participants will be randomized with a 1:1:1:1 allocation to receive 1 of 3 doses of selonsertib (2 mg, 6 mg, or 18 mg) or matching placebo.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
334

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jun 2014

Geographic Reach
2 countries

105 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2014

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

June 26, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 30, 2014

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2016

Completed
2.9 years until next milestone

Results Posted

Study results publicly available

June 11, 2019

Completed
Last Updated

November 5, 2019

Status Verified

October 1, 2019

Enrollment Period

2.1 years

First QC Date

June 26, 2014

Results QC Date

May 23, 2019

Last Update Submit

October 23, 2019

Conditions

Keywords

Diabetic Kidney DiseaseGilead

Outcome Measures

Primary Outcomes (1)

  • Change in eGFR From Baseline at Week 48

    The values of eGFR were calculated using the MDRD equation: eGFR = 175 x Serum Creatinine\^-1.154 Ă— age\^-0.203 Ă— 1.212 (if participant is black) Ă— 0.742 (if female).

    Baseline; Week 48

Secondary Outcomes (1)

  • Percentage of Participants Achieving at Least a 30% Reduction From Baseline in Albuminuria (As Measured by Urine Albumin to Creatinine Ratio) at Week 48

    Baseline; Week 48

Study Arms (4)

Selonsertib 2 mg

EXPERIMENTAL

Participants will receive selonsertib 2 mg for 48 weeks.

Drug: Selonsertib

Selonsertib 6 mg

EXPERIMENTAL

Participants will receive selonsertib 6 mg for 48 weeks.

Drug: Selonsertib

Selonsertib 18 mg

EXPERIMENTAL

Participants will receive selonsertib 18 mg for 48 weeks.

Drug: Selonsertib

Placebo to match selonsertib

PLACEBO COMPARATOR

Participants will receive placebo to match selonsertib for 48 weeks.

Drug: Placebo to match selonsertib

Interventions

Tablets administered orally once daily

Also known as: GS-4997
Selonsertib 18 mgSelonsertib 2 mgSelonsertib 6 mg

Tablets administered orally once daily

Placebo to match selonsertib

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult male or females with prior diagnosis of Diabetic Kidney Disease
  • Type 2 diabetes mellitus diagnosis for at least 6 months
  • eGFR (MDRD) at screening ≥ 15 mL/min/1.73m\^2 to \< 60 mL/min/1.73m\^2
  • Urine albumin to creatinine ratio (UACR) as follows:
  • Stage/Stratum 3a: eGFR range 45 to \< 60 mL/min; UACR ≥ 600 mg/g
  • Stage/Stratum 3b: eGFR range 30 to \< 45 mL/min; UACR ≥ 300 mg/g
  • Stage/Stratum 4: eGFR range 15 to \< 30 mL/min; UACR ≥ 150 mg/g
  • Receiving angiotensin-converting-enzyme inhibitor (ACEi) or angiotensin receptor blockers (ARB) at a minimum dose deemed appropriate for the individual by the investigator and be at a stable dose for the last three months
  • Individuals not on ACEi/ARB may be screened if there is documented intolerance to ACE inhibitor and/or ARB

You may not qualify if:

  • Type 1 diabetes mellitus
  • HbA1c \> 9.5%
  • Non-diabetic kidney disease
  • UACR \> 5000 mg/g on any measurement during screening
  • End stage renal disease (ESRD; receiving peritoneal dialysis, hemodialysis, or status post renal transplantation) or anticipated to occur within the treatment period
  • Unstable cardiovascular disease
  • Pregnant or lactating females

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (105)

The University of Alabama at Birmingham (UAB)

Birmingham, Alabama, 35294, United States

Location

Chase Medcare

Huntsville, Alabama, 35811, United States

Location

Choice Medicine

Toney, Alabama, 35773, United States

Location

Akdhc Medical Research Services, Llc

Peoria, Arizona, 85381, United States

Location

Akdhc Medical Research Services, Llc

Phoenix, Arizona, 85012, United States

Location

Akdhc Medical Research Services, Llc

Phoenix, Arizona, 85027, United States

Location

Akdhc Medical Research Services, Llc

Prescott, Arizona, 86301, United States

Location

Robert J. Bloomberg, MD

Tempe, Arizona, 85283, United States

Location

AKDHC East Office

Tucson, Arizona, 85712, United States

Location

Clinical Research Connections, LLC

Harrisburg, Arkansas, 72432, United States

Location

North America Research Institute

Azusa, California, 91702, United States

Location

California Institute of Renal Research

Chula Vista, California, 91910, United States

Location

California Institute of Renal Research Inc.

El Centro, California, 92243, United States

Location

Renal Consultants Medical Group Granada Hills

Granada Hills, California, 91344, United States

Location

Torrance Clinical Research

Lomita, California, 90717, United States

Location

IMD Medical Group

Los Angeles, California, 90020, United States

Location

Academic Medical Research Institute

Los Angeles, California, 90022, United States

Location

Kidney Research Center

Lynwood, California, 90262, United States

Location

Apex Research of Riverside

Riverside, California, 92505, United States

Location

San Francisco General Hospital

San Francisco, California, 94110, United States

Location

Clearview Medical Research, LLC

Santa Clarita, California, 91350, United States

Location

American Institute of Research

Whittier, California, 90603, United States

Location

Omega Research Consultants

DeBary, Florida, 32713, United States

Location

Creekside Medical Research

DeLand, Florida, 32720, United States

Location

Riverside Clinical Research

Edgewater, Florida, 32132, United States

Location

ASA Clinical Research

Jupiter, Florida, 33458, United States

Location

FPA Clinical Research

Kissimmee, Florida, 34741, United States

Location

The Chappel Group LLC

Kissimmee, Florida, 34741, United States

Location

South Florida Research Institute

Lauderdale Lakes, Florida, 33313, United States

Location

Prestige Clinical Research Center Inc

Miami, Florida, 33133, United States

Location

International Physicians Research / Nephrology Associates of South Miami

Miami, Florida, 33173, United States

Location

Tellus Clinical Research, Inc

Miami, Florida, 33173, United States

Location

Coral Research Clinic Corp

Miami, Florida, 33175, United States

Location

Suncoast Clinical Research, Inc.

New Port Richey, Florida, 34652, United States

Location

Discovery Medical Research Group

Ocala, Florida, 34471, United States

Location

Central Florida Internists

Orlando, Florida, 32811, United States

Location

Sunset Point Medical Associates DBA

Palm Harbor, Florida, 34684, United States

Location

Pines Clinical Research Inc.

Pembroke Pines, Florida, 33028, United States

Location

Central Florida Internists

Saint Cloud, Florida, 34769, United States

Location

Florida Pulmonary Research Institute

Winter Park, Florida, 32789, United States

Location

Rockdale Medical Research Associates

Conyers, Georgia, 30094, United States

Location

John H. Stroger Jr. Hospital Of Cook County

Chicago, Illinois, 60612, United States

Location

Midwest Endocrinology

Crystal Lake, Illinois, 60012, United States

Location

Beacon Medical Group Kidney and Hypertension Center

Mishawaka, Indiana, 46544, United States

Location

West Broadway Clinic

Council Bluffs, Iowa, 51501, United States

Location

Hutchinson Clinic, P.A

Hutchinson, Kansas, 67502, United States

Location

Kansas Nephrology Research Institute, LLC

Wichita, Kansas, 67214, United States

Location

L-MARC Research Center

Louisville, Kentucky, 40213, United States

Location

Four Rivers Clinical Research

Paducah, Kentucky, 42003, United States

Location

Research Nurse Specialists, LLc

Lafayette, Louisiana, 70503, United States

Location

Crescent City Clinical Research Center

Metairie, Louisiana, 70006, United States

Location

Tulane University

New Orleans, Louisiana, 70112, United States

Location

Internal Medicine Specialists

New Orleans, Louisiana, 70115, United States

Location

Green Clinic LLC

Ruston, Louisiana, 71270, United States

Location

Northwest Louisiana Nephrology

Shreveport, Louisiana, 71101, United States

Location

Southern Clinical Research

Zachary, Louisiana, 70791, United States

Location

Johns Hopkins Hospital/University

Baltimore, Maryland, 21205, United States

Location

A. Kaldun Nossuli MD Research

Bethesda, Maryland, 20814, United States

Location

Wayne State University

Detroit, Michigan, 48201, United States

Location

Apex Medical Research.Com

Flint, Michigan, 48504, United States

Location

Elite Clinical Research

Flint, Michigan, 48532, United States

Location

Troy Internal Medicine, PC

Troy, Michigan, 48098, United States

Location

VA Medical Center

Kansas City, Missouri, 64128, United States

Location

Mercury Street Medical Group, PLLC, Big Sky Clinical Research, LLC

Butte, Montana, 59701, United States

Location

Alegent Creighton Health

Omaha, Nebraska, 68131, United States

Location

Creighton Diabetes Center

Omaha, Nebraska, 68131, United States

Location

Nephrology and Hypertension Associates of New Jersey

Voorhees Township, New Jersey, 08043, United States

Location

Albuquerque Clinical Trials

Albuquerque, New Mexico, 87102, United States

Location

Nephrology Associates, PC

Flushing, New York, 11355, United States

Location

Mountain Kidney and Hypertension Associates

Asheville, North Carolina, 28801, United States

Location

Boice-Willis Clinic

Rocky Mount, North Carolina, 27804, United States

Location

Carolina Research Center

Shelby, North Carolina, 28150, United States

Location

Hightop Medical Research Center

Cincinnati, Ohio, 45231, United States

Location

Craig S Thompson MD LLC

Marion, Ohio, 43302, United States

Location

Your Diabetes Endocrine Nutrition Group Inc

Mentor, Ohio, 44060, United States

Location

Chris Sholer, MD, PC

Oklahoma City, Oklahoma, 73116, United States

Location

Bend Memorial Clinic

Bend, Oregon, 97701, United States

Location

Southeast Renal Research Institute

Chattanooga, Tennessee, 37408, United States

Location

Knoxville Kidney Center

Knoxville, Tennessee, 37923, United States

Location

Arlington Nephrology

Arlington, Texas, 76015, United States

Location

MW Clinical Research Center

Beaumont, Texas, 77701, United States

Location

Padre Coast Clinical Research

Corpus Christi, Texas, 78404, United States

Location

Corsicana Medical Research, PLLC

Corsicana, Texas, 75110, United States

Location

Texas Tech Univ. Health Sciences Center

El Paso, Texas, 79905, United States

Location

TVC Clinical Research

Gonzales, Texas, 78629, United States

Location

Diagnostic Clinic of Houston

Houston, Texas, 77004, United States

Location

Mercury Clinical Research

Houston, Texas, 77036, United States

Location

Lakewood Family Practice

Houston, Texas, 77070, United States

Location

Southwest Clinical Trials

Houston, Texas, 77074, United States

Location

Southwest Houston Research, Ltd.

Houston, Texas, 77099, United States

Location

HMRI CCAT Pearland

Pearland, Texas, 77584, United States

Location

Clinical Advancement Center, PLLC

San Antonio, Texas, 78215, United States

Location

Briggs Clinical Research, LLC

San Antonio, Texas, 78224, United States

Location

San Antonio Kidney Disease Center Physicians Group, P.L.L.C.

San Antonio, Texas, 78229, United States

Location

University of Texas Health Science Center at San Antonio

San Antonio, Texas, 78229, United States

Location

Val R. Hansen, M.D.

Bountiful, Utah, 84010, United States

Location

Fletcher Allen Health Care

Burlington, Vermont, 05401, United States

Location

University of Virginia

Charlottesville, Virginia, 22908, United States

Location

University of Wisconsin

Madison, Wisconsin, 53713, United States

Location

Zablocki VAMC

Milwaukee, Wisconsin, 53295, United States

Location

BC Diabetes

Vancouver, British Columbia, V5Z1M9, Canada

Location

Co-Medica Research Network

Courtice, Ontario, L1E 3C3, Canada

Location

Clinical Research Solutions, Inc.

Kitchener, Ontario, N2H 5Z8, Canada

Location

OTT Healthcare Inc.

Scarborough Village, Ontario, M1H 3G4, Canada

Location

Toronto East General Medical Centre

Toronto, Ontario, Canada

Location

Related Publications (2)

  • Chertow GM, Pergola PE, Chen F, Kirby BJ, Sundy JS, Patel UD; GS-US-223-1015 Investigators. Effects of Selonsertib in Patients with Diabetic Kidney Disease. J Am Soc Nephrol. 2019 Oct;30(10):1980-1990. doi: 10.1681/ASN.2018121231. Epub 2019 Sep 10.

  • Tesch GH, Ma FY, Han Y, Liles JT, Breckenridge DG, Nikolic-Paterson DJ. ASK1 Inhibitor Halts Progression of Diabetic Nephropathy in Nos3-Deficient Mice. Diabetes. 2015 Nov;64(11):3903-13. doi: 10.2337/db15-0384. Epub 2015 Jul 15.

MeSH Terms

Conditions

Diabetic Nephropathies

Interventions

selonsertib

Condition Hierarchy (Ancestors)

Kidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System Diseases

Results Point of Contact

Title
Gilead Clinical Study Information Center
Organization
Gilead Sciences

Study Officials

  • Gilead Study Director

    Gilead Sciences

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 26, 2014

First Posted

June 30, 2014

Study Start

June 1, 2014

Primary Completion

July 1, 2016

Study Completion

August 1, 2016

Last Updated

November 5, 2019

Results First Posted

June 11, 2019

Record last verified: 2019-10

Locations